MedTrace Logo

Medication Development in Alcoholism: Investigating PPAR Agonists

NCT02158273 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-06-02

Study results available
· View outcomes & findings →

Summary

The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to placebo.

Conditions

  • Alcoholism

Interventions

DRUG

Sugar Pill

145 mg/day, oral pill, 9 days

DRUG

TRICOR (fenofibrate)

145 mg/day, oral pill, 9 days

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • The Scripps Research Institute

    lead OTHER

Principal Investigators

  • Barbara J. Mason, Ph.D. · The Scripps Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02158273 on ClinicalTrials.gov